INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2012

Curcumin reduced clinical and endoscopic activity scores in quiescent ulcerative colitis.

A systematic review identified one randomized trial evaluating 2 g/day of oral curcumin alongside standard therapy in 89 patients with quiescent ulcerative colitis. Relapse occurred in 4% of curcumin patients versus 18% with placebo at six months (RR 0.24, 95% CI 0.05 to 1.09; P = 0.06), with no difference at 12 months (RR 0.70, 95% CI 0.35 to 1.40). At six months, curcumin significantly reduced clinical activity (MD -1.20, 95% CI -2.14 to -0.26) and endoscopic scores (MD -0.80, 95% CI -1.33 to -0.27).

Study type
Systematic review of randomized controlled trials
Who was studied
89 patients with quiescent ulcerative colitis (1 trial)
What was measured
Relapse rates and clinical and endoscopic activity indices

THE PAPER

Curcumin for maintenance of remission in ulcerative colitis.

Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC. Cochrane Database Syst Rev, 2012.

PubMed 23076948 ↗DOI 10.1002/14651858.CD008424.pub2 ↗

Gut & microbiome

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.